Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Genitourinary 1Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 6Neoplasms 3Neoplasm Metastasis 2Liver Neoplasms 2Colorectal Neoplasms 2Solid Tumors 1Sarcoma 1Pyloric Stenosis, Hypertrophic 1Gastrointestinal Neoplasms 1Carcinoma, Transitional Cell 1Advanced Hepatocellular Carcinoma (HCC) 1Adenocarcinoma Of Esophagus 1

Interventions

Fluorouracil 12pembrolizumab 9Oxaliplatin 9Nivolumab 9Leucovorin 8Capecitabine 7Cisplatin 6Trastuzumab 4Paclitaxel 3Drug Therapy 3Docetaxel 3zimberelimab 2zanidatamab 2tucatinib 2spartalizumab 2durvalumab 2Radiotherapy 2Levoleucovorin 2Irinotecan 2Gemcitabine 2Carboplatin 2130-nm albumin-bound paclitaxel 2zolbetuximab 1trifluridine tipiracil drug combination 1trastuzumab deruxtecan 1toripalimab 1tislelizumab 1tezacitabine 1ribociclib 1quemliclustat 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Adenocarcinoma Of Esophagus × brivanib × Clear all
NCT00633789 2015-10-09

Phase II Study of Brivanib (BMS-582664) to Treat Multiple Tumor Types

Bristol-Myers Squibb

Phase 2 Completed
597 enrolled
GastrointestinalGenitourinarySarcoma

Adenocarcinoma Of Esophagus, Carcinoma, Transitional Cell, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡